HomeOpen Access NewsMedical Treatment

Medical Treatment

Subscribe to Updates

Rebalancing wound care: Challenging the overuse of sub-therapetic compression through evidence based pathways

Health & Social Care
Adam Mence from L&R Medical UK walks us through rebalancing wound care, explaining the challenge of overusing sub-therapeutic compression through evidence-based pathways.

European Medicines Agency say AstraZeneca does not cause blood clots

Health & Social Care
The safety committee of the European Medicines Agency said the investigation did not prove that AstraZeneca vaccinations cause blood clots - describing the possibility as an "extremely small likelihood".

European Medicines Agency says AstraZeneca vaccine still safe to use

Health & Social Care
Over the weekend, the Republic of Ireland suspended their use of AstraZeneca due to reports of blood clots in Norway - in response, the European Medicines Agency (EMA) says the AstraZeneca vaccine is still safe to use.

Novavax 96.4% effective against the original COVID mutation

Research & Innovation
The US based vaccine appears to be 96.4% effective against the original COVID mutation, with 86% efficacy against the UK variant and only 55% against the South African variant.

Digital Therapies: How have digital mental health treatments evolved?

Mental Health
Rosie Copland-Mann, Creative Strategist at Rehab, discusses how digital therapies for mental health treatment has evolved, with a special focus on COVID-19.

Cancer treatment: Radiotherapy

Cancer Research
Cancer Centre London’s Keisha Robinson spoke to Open Access Government about cancer treatment in the UK today, in particular, radiotherapy.

Scientists find that elevated neutrophils can predict severe COVID and death

Research & Innovation
Researchers at Yale believe that blood tests could predict severe or critical COVID cases, because blood holds a series of interesting biological signals about a person.

The window for convalescent plasma donation is just under two months

Research & Innovation
New data suggests that before 60 days of COVID symptoms beginning is the best window for convalescent plasma donation - which is how antibodies were created in countless COVID-19 patients before vaccines.

The promises and challenges of biomodifying technologies for the UK

Research & Innovation
Michael Morrison, Senior Researcher in Social Science at the Centre for Health, Law and Emerging Technologies (HeLEX), University of Oxford, sheds light on the promises as well as biomodifying technologies for the UK.

Pfizer vaccine can reduce COVID hospitalisation and death by 75%

Health & Social Care
Early stage data from the vaccine rollout in the UK appears to show that COVID hospitalisation and death are reduced by over 75% in people with the Pfizer vaccine.

Scientists identify possible drug to fight incurable childhood cancer

Research & Innovation
Diffuse Intrinsic Pontine Glioma (DIPG) is an incurable childhood cancer that has no effective treatment - but now, scientists in Australia believe they have found a drug that could begin to treat this cancer.

People with obesity nearly three times as likely to get Type 2 diabetes

Health & Social Care
New research by the American Heart Association finds that obesity is a factor in almost half of all new cases, with obese individuals significantly more likely to get Type 2 diabetes.

The impact of the COVID-19 pandemic on cancer treatment

Cancer Research
Experts from the International Agency for Research on Cancer and the University of Molise chart the impact of the COVID-19 pandemic on cancer treatment.

The challenge of diagnosing depression could be solved by machines

Mental Health
Machine learning could be the solution to the "big challenges" of accurately diagnosing depression, say scientists at the University of Birmingham.

Scientists saw COVID mutating in patient after convalescent plasma

Research & Innovation
UK based scientists witnessed how COVID-19 can mutate in a highly vulnerable patient, even when that person is undergoing convalescent plasma treatment.

UK collaboration will revolutionise rare disease treatment

Diseases & Conditions
The Medicines Manufacturing Innovation Centre (MMIC) has developed a scalable, sustainable and more cost-effective way to manufacture oligonucleotides and treat rare diseases.

Research says 12 weeks between AstraZeneca doses improves protection

Health & Social Care
AstraZeneca dose efficiency holds at 76% in the three-month period between the first and second dose - suggesting that this time period is good for maximising protection.
1...91011Page 13 of 11

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders

Visit Article Archive
Open Access Government

Open Access Government produces compelling and informative news, publications, eBooks, and academic research articles for the public and private sector looking at health, diseases & conditions, workplace, research & innovation, digital transformation, government policy, environment, agriculture, energy, transport and more.

Follow Us

Resources

Quick Links

Legal & Marketing

As a Crossref Sponsored Member we are able to connect your content with a global network of online scholarly research, currently over 20,000 other organizational members from 160 countries. Crossref drive metadata exchange and support nearly 2 billion monthly API queries, facilitating global research communication.

© Adjacent Digital Politics Ltd